BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF

The pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license and option deal with ...